Bilateral Masculine Mastoplasia Associated with Imatinib Mesylate： A Case Report and Literature Review

1 CASE REPORT In June 2009, a 29-year-old Chinese male was diagnosed as having Philadelphia chromosome-positive chronic myeloid leukemia （chronic phase）; other than a high white blood cell count in peripheral blood （WBC, 254.00×10^9/L） and splenomegaly, the patient exhibited no abnormal physical sig...

Full description

Saved in:
Bibliographic Details
Published inJournal of Huazhong University of Science and Technology. Medical sciences Vol. 31; no. 1; pp. 145 - 146
Main Author 赵丹 王高翔 李春蕊 孟力
Format Journal Article
LanguageEnglish
Published Heidelberg Huazhong University of Science and Technology 01.02.2011
Subjects
Adult
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Benzamides
Gynecomastia - chemically induced
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Male
Medicine
Medicine & Public Health
Piperazines - adverse effects
Piperazines - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
乳腺增生
双边
外周血白细胞
文献
甲磺酸
病例报告
白血病
细胞计数
masculine mastoplasia
imatinib mesylate
side effect
Online AccessGet full text
ISSN1672-0733
1993-1352
DOI10.1007/s11596-011-0167-z

Cover

More Information
Summary:1 CASE REPORT In June 2009, a 29-year-old Chinese male was diagnosed as having Philadelphia chromosome-positive chronic myeloid leukemia （chronic phase）; other than a high white blood cell count in peripheral blood （WBC, 254.00×10^9/L） and splenomegaly, the patient exhibited no abnormal physical signs in mammary glands. He was given hydroxyurea for several days before he received treatment with 400 mg of imatinib mesylate daily.
Bibliography:masculine mastoplasia; imatinib mesylate; side effect
1 CASE REPORT In June 2009, a 29-year-old Chinese male was diagnosed as having Philadelphia chromosome-positive chronic myeloid leukemia （chronic phase）; other than a high white blood cell count in peripheral blood （WBC, 254.00×10^9/L） and splenomegaly, the patient exhibited no abnormal physical signs in mammary glands. He was given hydroxyurea for several days before he received treatment with 400 mg of imatinib mesylate daily.
42-1679/R
Dan ZHAO , Gaoxiang WANG , Chunrui LI , Li MENG （1 Department of Hemotology, Tongji Hospital, Tongji Medical College, Huangzhong University of Science and Technology, Wuhan 430030, China）
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Review-5
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1672-0733
1993-1352
DOI:10.1007/s11596-011-0167-z